TAIPEI (TVBS News) — The Taiwan Food and Drug Administration (FDA) reassured the public on Tuesday (Oct. 10) that the nation has a sufficient medication supply in the wake of the Israeli-Palestinian conflict.
The ongoing Israeli-Palestinian conflict has impacted the pharmaceutical industry worldwide and raised concerns regarding potential medication shortages in Taiwan.
In response, FDA Deputy Director-General, Chen Hui-fang, stated that current assessments suggest the conflict will not impact Taiwan's national medicine supply for the time being.
Pharmacist Huang Yen-ju pointed out that Azilect, an Israeli-produced medication primarily used to treat Parkinson's disease, may experience disruptions due to the ongoing conflict. Fortunately, a domestically-produced alternative named Rakinson is readily available.
Recognizing the uncertainty about the conflict's duration, the Ministry of Foreign Affairs (MOFA) disclosed that discussions regarding a citizen evacuation plan are in progress. They pledged to provide further updates in forthcoming press releases.
